Compare Ascendis Pharma A/S (ASND) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Home Depot Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Home Depot Inc trades at $354.5 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 20.8× Ascendis Pharma A/S's market cap, and Home Depot Inc pays a 2.66% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HD | |
|---|---|---|
Market Cap | $16.78B | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $423.42 |
52-Week Low | $189.74 | $297.51 |
Enterprise Value | $17.15B | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in 2025 revenue with solid profitability metrics including 8.41% net income margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations set at $4.73 EPS. The stock faces headwinds from weakening big-ticket demand and rising mortgage rates, but maintains strong analyst support with 59% buy ratings.
Home Depot presents a compelling long-term investment case with stable fundamentals and professional segment growth potential, though near-term challenges include housing market sensitivity and margin pressure. The consensus price target of $368.75 suggests 5.1% upside potential from current levels, supported by strong cash flow generation and dividend payments. Key risks include consumer spending volatility and competitive pressures in the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
